No Detail Found!

Indoleamine 2, 3-dioxygenase: Potential in cancer immunotherapy.

Author(s)
Abdul Majid Qureshi COMSATS Headquarters, 4th Floor, Sharah-e-Jamhuriat, Sector G-5/2, Islamabad, Pakistan
Kaenat Nasir Atta-ur-Rehman School of Applied Biosciences, National University of Science and Technology, Islamabad, Pakistan
Amnah Mahroo Atta-ur-Rehman School of Applied Biosciences, National University of Science and Technology, Islamabad, Pakistan
Bilal Zulfiqar Atta-ur-Rehman School of Applied Biosciences, National University of Science and Technology, Islamabad, Pakistan
Kashif Asghar Atta-ur-Rehman School of Applied Biosciences, National University of Science and Technology, Islamabad, Pakistan
Abstract
Indoleamine 2, 3-dioxygenase (IDO) is a potent immunosuppressive enzyme that has a significant role in different types of cancers. There is evidence that shows its involvement in a number of infectious diseases and auto-immune disorders. In vitro and in vivo studies indicate that 1-methyl tryptophan, being a competitive inhibitor, has shown to actively control the conditions in which IDO is over-expressed. Dendritic cells are the natural site of secretion of IDO in the host immune system. However, the expression takes place only in the presence of tolerogenic signals that lead to suppression of T-cell mediated immunogenic responses. Different therapies are being designed by employing the role of IDO in conditions such as stress, depression, cancer, pregnancy, and organ transplant, which reflect the promising role of this new target in cancer immunotherapy.
Publication Details
Page(s) 33-40
DOI DOI not available
Published Journal: Science Vision, Volume: 19, Issue: 1--2, Year: 2013

Request the full text from PASTIC

0

Citations

0

Downloads

17

Views